Cargando…

The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging

This study aimed to determine the predictive value of the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) based on biparametric magnetic resonance imaging (bpMRI) with combined target biopsy (TBx) and systematic biopsy (SBx) in patients with suspicion of having clinically significa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Daiki, Ozawa, Kaori, Takeuchi, Shinichi, Kawase, Makoto, Kawase, Kota, Nakai, Chie, Takai, Manabu, Iinuma, Koji, Nakane, Keita, Kato, Hiroki, Matsuo, Masayuki, Suzui, Natsuko, Miyazaki, Tatsuhiko, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025823/
https://www.ncbi.nlm.nih.gov/pubmed/33809967
http://dx.doi.org/10.3390/curroncol28020123
_version_ 1783675563200741376
author Kato, Daiki
Ozawa, Kaori
Takeuchi, Shinichi
Kawase, Makoto
Kawase, Kota
Nakai, Chie
Takai, Manabu
Iinuma, Koji
Nakane, Keita
Kato, Hiroki
Matsuo, Masayuki
Suzui, Natsuko
Miyazaki, Tatsuhiko
Koie, Takuya
author_facet Kato, Daiki
Ozawa, Kaori
Takeuchi, Shinichi
Kawase, Makoto
Kawase, Kota
Nakai, Chie
Takai, Manabu
Iinuma, Koji
Nakane, Keita
Kato, Hiroki
Matsuo, Masayuki
Suzui, Natsuko
Miyazaki, Tatsuhiko
Koie, Takuya
author_sort Kato, Daiki
collection PubMed
description This study aimed to determine the predictive value of the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) based on biparametric magnetic resonance imaging (bpMRI) with combined target biopsy (TBx) and systematic biopsy (SBx) in patients with suspicion of having clinically significant prostate cancer (csPCa). In this retrospective study, we reviewed the clinical and pathological records of 184 consecutive patients who underwent bpMRI before prostate biopsy. We focused on patients with PI-RADS v2 scores ≥ 3. MRI was performed using a 3-Tesla clinical scanner with a 32-channel phased-array receiver coil. PI-RADS v2 was used to describe bpMRI findings based on T2-weighted imaging and diffusion-weighted imaging scores. The primary endpoint was the diagnostic accuracy rate of PI-RADS v2 based on bpMRI for patients with prostate cancer (PCa) who underwent combined TBx and SBx. A total of 104 patients were enrolled in this study. Combined TBx and SBx was significantly superior to either method alone for PCa detection in patients with suspicious lesions according to PI-RADS v2. TBx and SBx detected concordant csPCa in only 24.1% of the patients. In addition, the rate of increase in the Gleason score was similar between SBx (41.5%) and TBx (34.1%). The diagnostic accuracy of bpMRI is comparable to that of standard multiparametric MRI for the detection of csPCa. Moreover, combined TBx and SBx may be optimal for the accurate determination of csPCa diagnosis, the International Society of Urological Pathology grade, and risk classification.
format Online
Article
Text
id pubmed-8025823
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80258232021-04-08 The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging Kato, Daiki Ozawa, Kaori Takeuchi, Shinichi Kawase, Makoto Kawase, Kota Nakai, Chie Takai, Manabu Iinuma, Koji Nakane, Keita Kato, Hiroki Matsuo, Masayuki Suzui, Natsuko Miyazaki, Tatsuhiko Koie, Takuya Curr Oncol Article This study aimed to determine the predictive value of the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) based on biparametric magnetic resonance imaging (bpMRI) with combined target biopsy (TBx) and systematic biopsy (SBx) in patients with suspicion of having clinically significant prostate cancer (csPCa). In this retrospective study, we reviewed the clinical and pathological records of 184 consecutive patients who underwent bpMRI before prostate biopsy. We focused on patients with PI-RADS v2 scores ≥ 3. MRI was performed using a 3-Tesla clinical scanner with a 32-channel phased-array receiver coil. PI-RADS v2 was used to describe bpMRI findings based on T2-weighted imaging and diffusion-weighted imaging scores. The primary endpoint was the diagnostic accuracy rate of PI-RADS v2 based on bpMRI for patients with prostate cancer (PCa) who underwent combined TBx and SBx. A total of 104 patients were enrolled in this study. Combined TBx and SBx was significantly superior to either method alone for PCa detection in patients with suspicious lesions according to PI-RADS v2. TBx and SBx detected concordant csPCa in only 24.1% of the patients. In addition, the rate of increase in the Gleason score was similar between SBx (41.5%) and TBx (34.1%). The diagnostic accuracy of bpMRI is comparable to that of standard multiparametric MRI for the detection of csPCa. Moreover, combined TBx and SBx may be optimal for the accurate determination of csPCa diagnosis, the International Society of Urological Pathology grade, and risk classification. MDPI 2021-03-22 /pmc/articles/PMC8025823/ /pubmed/33809967 http://dx.doi.org/10.3390/curroncol28020123 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Kato, Daiki
Ozawa, Kaori
Takeuchi, Shinichi
Kawase, Makoto
Kawase, Kota
Nakai, Chie
Takai, Manabu
Iinuma, Koji
Nakane, Keita
Kato, Hiroki
Matsuo, Masayuki
Suzui, Natsuko
Miyazaki, Tatsuhiko
Koie, Takuya
The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging
title The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging
title_full The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging
title_fullStr The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging
title_full_unstemmed The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging
title_short The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging
title_sort utility of combined target and systematic prostate biopsies in the diagnosis of clinically significant prostate cancer using prostate imaging reporting and data system version 2 based on biparametric magnetic resonance imaging
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025823/
https://www.ncbi.nlm.nih.gov/pubmed/33809967
http://dx.doi.org/10.3390/curroncol28020123
work_keys_str_mv AT katodaiki theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT ozawakaori theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT takeuchishinichi theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT kawasemakoto theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT kawasekota theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT nakaichie theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT takaimanabu theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT iinumakoji theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT nakanekeita theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT katohiroki theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT matsuomasayuki theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT suzuinatsuko theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT miyazakitatsuhiko theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT koietakuya theutilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT katodaiki utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT ozawakaori utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT takeuchishinichi utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT kawasemakoto utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT kawasekota utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT nakaichie utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT takaimanabu utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT iinumakoji utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT nakanekeita utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT katohiroki utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT matsuomasayuki utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT suzuinatsuko utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT miyazakitatsuhiko utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging
AT koietakuya utilityofcombinedtargetandsystematicprostatebiopsiesinthediagnosisofclinicallysignificantprostatecancerusingprostateimagingreportinganddatasystemversion2basedonbiparametricmagneticresonanceimaging